Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

521. The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia

, Langham SJ, McKellar J, Awad AG. Patient satisfaction and acceptability of long-term treatment with quetiapine. International Journal of Psychiatry in Clinical Practice 1999;3:105-13. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry 1993;150:1630-8. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients (...) The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia Lynch J, Morrison J, Graves N, Meddis D, Drummond M F, Hellewell J S E Record Status

2001 NHS Economic Evaluation Database.

522. Cognitive therapy for psychosis in schizophrenia: an effect size analysis

Cognitive therapy for psychosis in schizophrenia: an effect size analysis Cognitive therapy for psychosis in schizophrenia: an effect size analysis Cognitive therapy for psychosis in schizophrenia: an effect size analysis Gould R A, Mueser K T, Bolton E, Mays V, Goff D Authors' objectives To undertake a meta-analysis of all available controlled treatment outcome studies of cognitive therapy (CT) for psychotic symptoms in schizophrenia. Searching PsycLIT (from 1974 to present) and MEDLINE (from (...) 1966 to present) were searched using the following combination of key terms: 'schizophrenia', 'psychosis', 'cognitive', 'cognitive-behavioural', 'treatment', 'treatment outcome', 'clinical trial' and 'comparative study'. These terms were used both as free-text forms and as major key terms in searching the database. The reference lists of the located articles were examined for additional studies. Unpublished articles were sought by examining Dissertation Abstracts from 1980 to the present. Articles

2001 DARE.

523. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials

; Antipsychotic Agents /pharmacology /therapeutic use; Controlled Clinical Trials as Topic; Hostility; Humans; Risperidone /pharmacology /therapeutic use; Schizophrenia /drug therapy; Schizophrenic Psychology AccessionNumber 12001006160 Date bibliographic record published 31/05/2003 Date abstract record published 31/05/2003 Record Status This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods (...) Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials Aleman A, Kahn R S Authors' objectives To evaluate the published evidence regarding the effects

2001 DARE.

524. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia

Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia Oh P I, Lanctot K L, Mittmann N, Iskedjian M, Einarson T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of risperidone (RIS) to ameliorate the negative symptoms of schizophrenia. Risperidone is a benzisoxazole derivative with combined serotonin and dopamine receptor blocking properties. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population

2001 NHS Economic Evaluation Database.

525. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis

Journal of Psychiatry 1994;151:20-6. Conley RR, Schultz SC, Baker RW, Collins JF, Bell JA. Clozapine efficacy in schizophrenic nonresponders. Psychopharmacology Bulletin 1988;24:269-74. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatrica Scandinavica 1995;92:199-201. Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison (...) Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis Oh P I, Iskedjian M, Addis A, Lanctot K, Einarson T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

2001 NHS Economic Evaluation Database.

526. Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study

Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study Kasper S, Jones M, Duchesne I Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of either risperidone or olanzapine for the treatment of patients with schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised hospitalised patients aged 65

2001 NHS Economic Evaluation Database.

527. Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling

Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling Alexeyeva I, Mauskopf J, Earnshaw S R, Stauffer V L, Gibson J P, Ascher-Svanum H, Ramsey J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of olanzapine and ziprasidone for the treatment of schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with acute-episode schizophrenia. Further inclusion and exclusion criteria were

2001 NHS Economic Evaluation Database.

528. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes

Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitude Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please

2001 NIHR HTA programme

529. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. (Abstract)

Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. 12 patients with schizophrenia and auditory hallucinations received 1 Hz transcranial magnetic stimulation of left temporoparietial cortex. In a double-blind crossover trial, active stimulation significantly reduced hallucinations relative to sham stimulation.

2000 Lancet Controlled trial quality: uncertain

530. Psychoeducation for schizophrenia. Full Text available with Trip Pro

Psychoeducation for schizophrenia. Schizophrenia can be a severe and chronic illness characterised by lack of insight and poor compliance with treatment. Psychoeducational approaches have been developed to increase patients' awareness of their illness and its treatment.To assess the effects of psychoeducational interventions compared to standard levels of knowledge provision.Electronic searches of CINAHL (1982-1999), The Cochrane Library CENTRAL (Issue 1, 1999), The Cochrane Schizophrenia (...) Group's Register (January 1999), EMbase (1980-1999), MEDLINE (1966-1999), PsycLit (1974-1999), and Sociofile (1974-1999) were undertaken. These were supplemented with reference searching and personal contact with authors of all included studies.All relevant randomised controlled trials focusing on psychoeducation for schizophrenia or related serious mental illnesses, involving individuals or groups. Quasi-randomised trials were excluded.Data were extracted independently by at least two reviewers from

2000 Cochrane

531. Token economy for schizophrenia. (Abstract)

Token economy for schizophrenia. A token economy is a behavioural therapy technique in which the desired change is achieved by means of tokens administered for the performance of predefined behaviours according to a program. Though token economy programmes were widespread in the 1970s they became largely restricted to wards where long-stay patients from institutions are prepared for transfer into the community and were particularly aimed at changing negative symptoms of schizophrenia - poor (...) motivation, poor attention and social withdrawal.To review the effects of token economies for people with schizophrenia, or other serious or chronic mental illnesses, compared with standard care.Electronic searches of Biological Abstracts (1985-1999), CINAHL (1982-1998), The Cochrane Library (Issue 1, 1999), The Cochrane Schizophrenia Group's Register of Trials (February 1999), EMBASE (1980-1999) and PsycLIT (1987-1998) were supplemented with reference searches, personal contact with trial authors

2000 Cochrane

532. Thioridazine for schizophrenia. (Abstract)

Thioridazine for schizophrenia. Thioridazine is a piperidine phenothiazine used for the treatment of people with schizophrenia. It has often been considered the drug of choice in the elderly because of reputed lower levels of extrapyramidal adverse events. It may, however, be more likely to cause cognitive adverse events, such as delirium or worsening of memory, and, on rare occasions, thioridazine has caused pigmentary retinopathy.To examine the effects of thioridazine for those (...) with schizophrenia, and, in particular, elderly people with schizophrenia.Electronic searches of Biological Abstracts (1980-1999), CINAHL (1982-1999), The Cochrane Library (Issue 3, 1999), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), PsycLIT (1974-1999) and Sociofile (1974-1999) were undertaken. References of all identified studies were searched for further trials. Pharmaceutical companies and authors of trials were contacted.All randomised clinical trials

2000 Cochrane

533. Risperidone versus other atypical antipsychotic medication for schizophrenia. (Abstract)

Risperidone versus other atypical antipsychotic medication for schizophrenia. Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other atypical (...) antipsychotic drugs such as clozapine.To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar and Dialog

2000 Cochrane

534. Cognitive rehabilitation for people with schizophrenia and related conditions. Full Text available with Trip Pro

Cognitive rehabilitation for people with schizophrenia and related conditions. Researchers have consistently found that people with schizophrenia score more poorly than others on a wide array of cognitive tasks and that these deficits persist even when the illness is in remission. The perceived impact of cognitive impairment on day-to-day functioning has led to the development of cognitive rehabilitation techniques intended to remedy these impairments, and thus improve the functioning of people (...) with schizophrenia.To determine whether the use of cognitive rehabilitation techniques is associated with improvement in people with schizophrenia and related conditions.Electronic searches of Biological Abstracts (1982-1997), the Cochrane Schizophrenia Group's Register of trials (2000), EMBASE (1980-1997), LILACS (1982-1997), MEDLINE (1966-1997), PsycLIT (1974-1997) and SCISEARCH (1997) were undertaken. References of all identified studies were handsearched and the first author of each included trial

2000 Cochrane

535. Antipsychotic medication for those with both schizophrenia and learning disability. (Abstract)

Antipsychotic medication for those with both schizophrenia and learning disability. Antipsychotic medication is the standard treatment for people with learning disability and schizophrenia.To determine the efficacy of any antipsychotic medication for treating people with a dual diagnosis of learning disability and schizophrenia.Electronic searching of Biological Abstracts, the Cochrane Schizophrenia Group's Register of trials, the Cochrane Library, EMBASE, PsycLIT and MEDLINE. Unpublished data (...) were sought from pharmaceutical companies. Both authors independently selected the relevant studies from the reports identified in this way.1. All randomised controlled trials of antipsychotic medication, regardless of dosage, versus a placebo control, of longer than one month's duration. 2. Anyone over 18 years of age with both learning disability and schizophrenia. Learning disability was defined as a measured IQ of 70 or less. Any mode of diagnosis of schizophrenia was acceptable.The two

2000 Cochrane

536. Risperidone versus typical antipsychotic medication for schizophrenia. Full Text available with Trip Pro

Risperidone versus typical antipsychotic medication for schizophrenia. The 'conventional' neuroleptic drugs, such as haloperidol and chlorpromazine, are frequently used as the first line treatment for people with schizophrenia. However, about 5-25% of these people show poor response to these treatments and side effects often makes compliance with the 'older generation' of drug treatment problematic. Although the efficacy of these medications with respect to 'positive' symptoms is well described (...) , little evidence exists that 'conventional' antipsychotic treatment has any effect on the 'negative' symptoms of schizophrenia. Risperidone is one of the 'new generation' neuroleptic compounds. As well as its reputed tendency to cause fewer movement disorders it is claimed that risperidone may improve negative symptoms.To evaluate the effectiveness of risperidone for schizophrenia in comparison to 'conventional' neuroleptic drugs.Electronic searches of Biological Abstracts (1980-1997), Cochrane

2000 Cochrane

537. Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses. (Abstract)

Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses. People with schizophrenia or other psychotic illnesses may have delusions or hallucinations that may lead them to be aggressive or violent to themselves or others. Medication that is used in this context require the properties of rapid onset of effect (tranquillisation or at least initial sedation in order to quell aggressive or disorganised behaviour, but also antipsychotic effect), low (...) to have these properties.To estimate the effectiveness of zuclopenthixol acetate for the acute treatment of serious mental illnesses in comparison to other neuroleptic drugs.Searches of the Cochrane Schizophrenia Group's Register of Trials, The Cochrane Library, MEDLINE, abstracts of congresses and trial reference lists were performed. Appeals for unpublished data to the research community and to the Medical Information Department of Lundbeck Limited were also made. Attempts were made to contact

2000 Cochrane

538. Newer atypical antipsychotic medication versus clozapine for schizophrenia. (Abstract)

Newer atypical antipsychotic medication versus clozapine for schizophrenia. Clozapine is an atypical antipsychotic drug, which is claimed to have superior efficacy and to cause fewer movement disorders. However, clozapine carries a significant risk of serious blood disorders. Newer atypical antipsychotics are safer alternatives that might share the benefits of clozapine. It is thus of interest to compare the effectiveness of newer atypical antipsychotics with the effectiveness of clozapine.To (...) evaluate the clinical effects of newer atypical antipsychotic drugs in comparison to clozapine for schizophrenia.Publications in all languages were searched from the following databases: Biological Abstracts/BIOSIS (1980-1999), The Cochrane Schizophrenia Group's Register of Trials (1998), The Cochrane Library CENTRAL Register (Issue 4, 1999), EMBASE (1980-1998), MEDLINE (1966-1999), LILACS/CD-ROM (1998), and PsycLIT/PsycINFO (1974-1999). Trials were also sought from recent conference proceedings

2000 Cochrane

539. Quetiapine for schizophrenia. (Abstract)

Quetiapine for schizophrenia. Quetiapine is a novel atypical antipsychotic with low propensity for movement disorder adverse effects. It is used for treatment of schizophrenia and other psychoses.To determine the effects of quetiapine for schizophrenia in comparison to placebo, classical and other atypical antipsychotics.Electronic searches of Biological Abstracts (1982-1997), CINAHL (1982-1997), the Cochrane Library (1998, Issue 1), the Cochrane Schizophrenia Group's Register of trials (1998 (...) ), EMBASE (1980-1998), MEDLINE (1966-1998), PsycLIT (1974-1997), SocioFile (1974-1997) and many conference proceedings and hand searches of specific journals were undertaken. Zeneca Pharmaceuticals was contacted for information regarding unpublished trials.All controlled trials where adults with schizophrenia or similar illnesses were randomised to quetiapine, placebo or other neuroleptic drugs and where clinically relevant outcomes were reported.Citations and, where possible, abstracts were

2000 Cochrane

540. Ziprasidone for schizophrenia and severe mental illness. (Abstract)

Ziprasidone for schizophrenia and severe mental illness. Typical antipsychotic drugs are widely used as the first line treatment for people with schizophrenia. However, the atypical class of antipsychotic drugs are making important inroads into this approach. Atypical is a widely used term used to describe some antipsychotics which have a low propensity to produce movement disorders, sedation and raised serum prolactin. There is some suggestion that the different adverse effect profiles (...) of the atypical antipsychotic group make them more acceptable to people with schizophrenia. Ziprasidone is one of the newer atypicals with a high serotonin/dopamine receptor affinity.To determine the effects of ziprasidone compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 1999), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999

2000 Cochrane